KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) EBITDA: 2009-2024

Historic EBITDA for Ionis Pharmaceuticals (IONS) over the last 16 years, with Dec 2024 value amounting to -$475.1 million.

  • Ionis Pharmaceuticals' EBITDA fell 7.75% to -$160.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$278.0 million, marking a year-over-year increase of 24.93%. This contributed to the annual value of -$475.1 million for FY2024, which is 34.31% down from last year.
  • Per Ionis Pharmaceuticals' latest filing, its EBITDA stood at -$475.1 million for FY2024, which was down 34.31% from -$353.7 million recorded in FY2023.
  • Ionis Pharmaceuticals' EBITDA's 5-year high stood at -$30.2 million during FY2021, with a 5-year trough of -$475.1 million in FY2024.
  • Moreover, its 3-year median value for EBITDA was -$410.2 million (2022), whereas its average is -$413.0 million.
  • As far as peak fluctuations go, Ionis Pharmaceuticals' EBITDA skyrocketed by 82.46% in 2021, and later slumped by 1,258.88% in 2022.
  • Over the past 5 years, Ionis Pharmaceuticals' EBITDA (Yearly) stood at -$172.1 million in 2020, then spiked by 82.46% to -$30.2 million in 2021, then plummeted by 1,258.88% to -$410.2 million in 2022, then increased by 13.76% to -$353.7 million in 2023, then tumbled by 34.31% to -$475.1 million in 2024.